Daver, N. G., Montesinos, P., Aribi, A., Martinelli, G., Altman, J., Roboz, G., Wang, E. S., Burke, P. W., Jeyakumar, D., Walter, R. B., DeAngelo, D. J., Erba, H. P., Advani, A., Gastaud, L., Thomas, X., Todisco, E., Pemmaraju, N., Mendez, L., de la Fuente, A., Gaidano, G., Curti, A., Boissel, N., Recher, C., Schliemann, C., Vyas, P., Sloss, C. M., Wang, J., Malcolm, K. A., Zweidler-McKay, P. A., & Sweet, K. L. (n.d.). p555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML. HemaSphere, 6, 454–455. http://access.bl.uk/ark:/81055/vdc_100159756651.0x000003